These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 36351175)

  • 1. Correction to "Targeted Theranostic
    Cheng MHY; Overchuk M; Rajora MA; Lou JWH; Chen Y; Pomper MG; Chen J; Zheng G
    Mol Pharm; 2023 Jan; 20(1):783. PubMed ID: 36351175
    [No Abstract]   [Full Text] [Related]  

  • 2. Targeted Theranostic
    Cheng MHY; Overchuk M; Rajora MA; Lou JWH; Chen Y; Pomper MG; Chen J; Zheng G
    Mol Pharm; 2021 Dec; ():. PubMed ID: 34965727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiolabeled Antibodies Against Müllerian-Inhibiting Substance Receptor, Type II: New Tools for a Theranostic Approach in Ovarian Cancer.
    Deshayes E; Ladjohounlou R; Le Fur P; Pichard A; Lozza C; Boudousq V; Sevestre S; Jarlier M; Kashani R; Koch J; Sosabowski J; Foster J; Chouin N; Bruchertseifer F; Morgenstern A; Kotzki PO; Navarro-Teulon I; Pouget JP
    J Nucl Med; 2018 Aug; 59(8):1234-1242. PubMed ID: 29674421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Theranostic Perspectives in Prostate Cancer with the Gastrin-Releasing Peptide Receptor Antagonist NeoBOMB1: Preclinical and First Clinical Results.
    Nock BA; Kaloudi A; Lymperis E; Giarika A; Kulkarni HR; Klette I; Singh A; Krenning EP; de Jong M; Maina T; Baum RP
    J Nucl Med; 2017 Jan; 58(1):75-80. PubMed ID: 27493272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mixed and Matched Metallo-Nanotexaphyrin for Customizable Biomedical Imaging.
    Keca JM; Valic MS; Cheng MHY; Jiang W; Overchuk M; Chen J; Zheng G
    Adv Healthc Mater; 2019 Mar; 8(6):e1800857. PubMed ID: 30211482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A radio-theranostic nanoparticle with high specific drug loading for cancer therapy and imaging.
    Satterlee AB; Yuan H; Huang L
    J Control Release; 2015 Nov; 217():170-82. PubMed ID: 26341695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical efficacy of hK2 targeted [
    Timmermand OV; Elgqvist J; Beattie KA; Örbom A; Larsson E; Eriksson SE; Thorek DLJ; Beattie BJ; Tran TA; Ulmert D; Strand SE
    Theranostics; 2019; 9(8):2129-2142. PubMed ID: 31149033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Theranostic Nanoparticles with Aggregation-Induced Emission and MRI Contrast Enhancement Characteristics as a Dual-Modal Imaging Platform for Image-Guided Tumor Photodynamic Therapy.
    Yang H; He Y; Wang Y; Yang R; Wang N; Zhang LM; Gao M; Jiang X
    Int J Nanomedicine; 2020; 15():3023-3038. PubMed ID: 32431499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Panitumumab Modified with Metal-Chelating Polymers (MCP) Complexed to
    Aghevlian S; Lu Y; Winnik MA; Hedley DW; Reilly RM
    Mol Pharm; 2018 Mar; 15(3):1150-1159. PubMed ID: 29314858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Multimodal Theranostic System Prepared from High-Density Lipoprotein Carrier of Doxorubicin and
    Quintos-Meneses HA; Aranda-Lara L; Morales-Ávila E; Ocampo-García B; Contreras I; Ramírez-Nava GJ; Santos-Cuevas CL; Estrada JA; Luna-Gutiérrez MA; Ferro-Flores G; Camacho-López MA; Torres-García E; Ramírez-Durán N; Isaac-Olivé K
    J Biomed Nanotechnol; 2021 Nov; 17(11):2125-2141. PubMed ID: 34906274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of the dead-time correction method on quantitative
    Desy A; Bouvet GF; Lafrenière N; Zamanian A; Després P; Beauregard JM
    EJNMMI Phys; 2022 Aug; 9(1):54. PubMed ID: 35976503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a Theranostic Convergence Bioradiopharmaceutical for Immuno-PET Based Radioimmunotherapy of L1CAM in Cholangiocarcinoma Model.
    Song IH; Jeong MS; Hong HJ; Shin JI; Park YS; Woo SK; Moon BS; Kim KI; Lee YJ; Kang JH; Lee TS
    Clin Cancer Res; 2019 Oct; 25(20):6148-6159. PubMed ID: 31337646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proof of Therapeutic Efficacy of a
    Schulz J; Rohracker M; Stiebler M; Goldschmidt J; Stöber F; Noriega M; Pethe A; Lukas M; Osterkamp F; Reineke U; Höhne A; Smerling C; Amthauer H
    J Nucl Med; 2017 Jun; 58(6):936-941. PubMed ID: 28254866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Theranostic polymeric nanoparticles for NIR imaging and photodynamic therapy.
    Sarcan ET; Silindir-Gunay M; Ozer AY
    Int J Pharm; 2018 Nov; 551(1-2):329-338. PubMed ID: 30244148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new class of PentixaFor- and PentixaTher-based theranostic agents with enhanced CXCR4-targeting efficiency.
    Osl T; Schmidt A; Schwaiger M; Schottelius M; Wester HJ
    Theranostics; 2020; 10(18):8264-8280. PubMed ID: 32724470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and evaluation of Lys¹(α,γ-Folate)Lys³(¹⁷⁷Lu-DOTA)-Bombesin(1-14) as a potential theranostic radiopharmaceutical for breast cancer.
    Aranda-Lara L; Ferro-Flores G; Azorín-Vega E; Ramírez FM; Jiménez-Mancilla N; Ocampo-García B; Santos-Cuevas C; Isaac-Olivé K
    Appl Radiat Isot; 2016 Jan; 107():214-219. PubMed ID: 26545016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel theranostic agent for PET imaging and targeted radiopharmaceutical therapy of tumour-infiltrating immune cells in glioma.
    Foster A; Nigam S; Tatum DS; Raphael I; Xu J; Kumar R; Plakseychuk E; Latoche JD; Vincze S; Li B; Giri R; McCarl LH; Edinger R; Ak M; Peddagangireddy V; Foley LM; Hitchens TK; Colen RR; Pollack IF; Panigrahy A; Magda D; Anderson CJ; Edwards WB; Kohanbash G
    EBioMedicine; 2021 Sep; 71():103571. PubMed ID: 34530385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative (177)Lu SPECT (QSPECT) imaging using a commercially available SPECT/CT system.
    Beauregard JM; Hofman MS; Pereira JM; Eu P; Hicks RJ
    Cancer Imaging; 2011 Jun; 11(1):56-66. PubMed ID: 21684829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative
    D'Arienzo M; Cozzella ML; Fazio A; De Felice P; Iaccarino G; D'Andrea M; Ungania S; Cazzato M; Schmidt K; Kimiaei S; Strigari L
    Phys Med; 2016 Dec; 32(12):1745-1752. PubMed ID: 27692753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 68Ga/177Lu-NeoBOMB1, a Novel Radiolabeled GRPR Antagonist for Theranostic Use in Oncology.
    Dalm SU; Bakker IL; de Blois E; Doeswijk GN; Konijnenberg MW; Orlandi F; Barbato D; Tedesco M; Maina T; Nock BA; de Jong M
    J Nucl Med; 2017 Feb; 58(2):293-299. PubMed ID: 27609789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.